Viatris

OverviewSuggest Edit

Viatris is a pharmaceuticals company. Its portfolio comprises molecules across a range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally-recognized brands, generic, complex generic and branded medicines, a portfolio of biosimilars, and a variety of over-the-counter consumer products. Viatris is a company formed by the combination of Mylan and Upjohn, a division of Pfizer.
TypePublic
Founded2020
HQCanonsburg, PA, US
Websiteviatris.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2021)37,000(-17%)
Job Openings735
Revenue (FY, 2021)$17.9 B(+50%)
Share Price (Jun 2022)$10.5(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Viatris

Michael Goettler

Michael Goettler

Chief Executive Officer, Director
Rajiv Malik

Rajiv Malik

President, Director
Sanjeev Narula

Sanjeev Narula

Chief Financial Officer
Paul Campbell

Paul Campbell

Chief Accounting Officer & Corporate Controller
Brian Roman

Brian Roman

Global General Counsel
Anil Amin

Anil Amin

Chief Business Development Officer
Show more

Viatris Office Locations

Viatris has offices in Canonsburg, Carole Park, Millers Point, Sofia and in 16 other locations
Canonsburg, PA, US (HQ)
1000 Mylan Blvd
Carole Park, AU
15 Garnet St
Millers Point, AU
Level 1, 30 The Bond, 30-34 Hickson Road
Sofia, BG
bul. "Sitnyakovo" 48
Toronto, CA
85 Advance Rd, Etobicoke
Beijing, CN
3-7 Chaoyangmen North Street, Dongcheng District
Show all (22)

Viatris Financials and Metrics

Viatris Revenue

Embed Graph
View revenue for all periods
Viatris's revenue was reported to be $17.89 b in FY, 2021 which is a 49.7% increase from the previous period.
USD

Revenue (Q1, 2022)

4.2b

Gross profit (Q1, 2022)

1.8b

Gross profit margin (Q1, 2022), %

42.3%

Net income (Q1, 2022)

399.2m

EBITDA (Q1, 2022)

1.6b

EBIT (Q1, 2022)

707.4m

Market capitalization (17-Jun-2022)

12.7b

Closing stock price (17-Jun-2022)

10.5

Cash (30-Jun-2021)

673.9m
Viatris's current market capitalization is $12.7 b.
Annual
USDFY, 2020FY, 2021

Revenue

11.9b17.9b

Revenue growth, %

50%

Cost of goods sold

8.1b12.3b

Gross profit

3.8b5.6b
Quarterly
USDQ1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

4.4b4.6b4.5b4.2b

Cost of goods sold

3.3b3.3b3.0b2.4b

Gross profit

1.1b1.3b1.6b1.8b

Gross profit Margin, %

25%29%35%42%
Annual
USDFY, 2020
Quarterly
USDQ2, 2021

Cash

673.9m

Accounts Receivable

4.5b

Prepaid Expenses

2.1b

Inventories

4.5b
Annual
USDFY, 2020FY, 2021

Net Income

(1.3b)

Depreciation and Amortization

4.5b

Inventories

(427.6m)

Accounts Payable

(70.4m)
Quarterly
USDQ1, 2021Q2, 2021Q3, 2021

Net Income

(1.3b)(1.0b)

Depreciation and Amortization

1.4b2.7b3.8b

Inventories

(203.4m)(351.1m)

Accounts Payable

191.9m(53.5m)(108.4m)
USDFY, 2020

Revenue/Employee

265.5k

P/E Ratio

(16.9)
Show all financial metrics

Viatris Operating Metrics

Viatris's Customers was reported to be 60 k in Dec, 2020.
Dec, 2020

Customers

60 k

Manufacturing Facilities

15

Molecules

1.4 k

SKUs Available

30 k

Viatris Acquisitions / Subsidiaries

Company NameDateDeal Size
Abbex AB.
Acton Pharmaceuticals, Inc.
Agila Australasia Pty Ltd.
Agila Specialties Inc..
Agila Specialties Investments Limited.
Alaven Pharmaceutical LLC.
Alphapharm Pty. Ltd.,
ALVP Holdings, LLC.
American Triumvirate Insurance Company.
Arcana Arzneimittel GmbH.
Show more

Viatris Revenue Breakdown

Embed Graph

Viatris revenue breakdown by business segment: 11.3% from JANZ, 58.3% from Developed Markets, 17.6% from Emerging Markets, 12.4% from Greater China and 0.4% from Other

Human Capital Metrics

Embed Graph

Viatris Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Viatris Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Viatris Online and Social Media Presence

Embed Graph

Viatris News and Updates

Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022....

Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022

PITTSBURGH, April 8, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer...

Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva

Approval continues track record of successful firsts in developing complex generic medicines to help increase patient access PITTSBURGH and ST. PAUL, Minn., March 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan...

Biocon Biologics' Viatris Deal To Aid Value Chain But Risks Persist: Analysts

Here's what analysts have to say about Biocon Biologics-Viatris deal.

Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion. The company said the move is the first in a planned series of asset sales t…

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

PITTSBURGH, Feb. 4, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will host its investor event the morning of Monday, February 28, 2022, beginning at 8:30 a.m. ET. During the event, Chief Executive Officer Michael Goettler, President Rajiv Malik and Chief Financial Officer Sanjeev...
Show more

Viatris Frequently Asked Questions

  • When was Viatris founded?

    Viatris was founded in 2020.

  • Who are Viatris key executives?

    Viatris's key executives are Michael Goettler, Rajiv Malik and Sanjeev Narula.

  • How many employees does Viatris have?

    Viatris has 37,000 employees.

  • What is Viatris revenue?

    Latest Viatris annual revenue is $17.9 b.

  • What is Viatris revenue per employee?

    Latest Viatris revenue per employee is $483.4 k.

  • Who are Viatris competitors?

    Competitors of Viatris include Amgen, Sanofi and Teva Pharmaceuticals.

  • Where is Viatris headquarters?

    Viatris headquarters is located at 1000 Mylan Blvd, Canonsburg.

  • Where are Viatris offices?

    Viatris has offices in Canonsburg, Carole Park, Millers Point, Sofia and in 16 other locations.

  • How many offices does Viatris have?

    Viatris has 22 offices.